Literature DB >> 2849969

Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma.

B J Lipworth1, R A Clark, D P Dhillon, R A Brown, D G McDevitt.   

Abstract

1. Fourteen asthmatics (mean +/- s.e. mean baseline FEV1 62 +/- 6% of predicted) were given cumulative doubling doses of salbutamol by metered-dose inhaler as follows: 100 micrograms, 200 micrograms, 500 micrograms, 1000 micrograms, 2000 micrograms, 4000 micrograms. 2. Airways, tremor, haemodynamic and cyclic AMP responses were measured at each dose increment (made every 20 min). 3. There was a linear log dose-response relationship for each airways parameter (FEV1, VC, sGaw, FEF 50%). The plateau in the dose-response curve was not reached within our dose range. These changes were also mirrored in cyclic AMP responses. 4. There was a wide range in maximum airways response expressed in terms of absolute increase over baseline (95% confidence intervals: delta FEV1 667-1483 ml; delta VC 689-1695 ml; delta sGaw 0.92-4.50 s-1 kPa-1; delta FEF 50% 0.94-2.15 l s-1). Patients with a lower baseline showed a greater response in terms of percent increase in FEV1 (r = -0.83, P less than 0.001). There was however, no correlation between baseline airway calibre and the dose required for maximum bronchodilatation. 5. There were objective increases (mean +/- s.e. mean) in both heart rate (maximum delta HR of 14 +/- 5 beats min-1 at 4000 micrograms) and tremor power (maximum delta Tr of 115 +/- 44% at 2000 micrograms). These were not dose limiting side-effects as subjective symptoms were infrequent at higher doses. 6. Higher than conventional doses of salbutamol given by metered-dose inhaler may produce a distinct improvement in airways response without significant side-effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2849969      PMCID: PMC1386629          DOI: 10.1111/j.1365-2125.1988.tb05292.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Evaluation of skeletal muscle tremor due to bronchodilator agents.

Authors:  G Thiringer; N Svedmyr
Journal:  Scand J Respir Dis       Date:  1975-08

2.  Lack of bronchial beta adrenoceptor resistance in asthmatics during long-term treatment with terbutaline.

Authors:  S Larsson; N Svedmyr; G Thiringer
Journal:  J Allergy Clin Immunol       Date:  1977-02       Impact factor: 10.793

3.  Comparative effects of ephedrine on adrenergic responsiveness in normal and asthmatic subjects.

Authors:  H G Morris; S A Rusnak; J C Selner; K Barzens; J Barnes
Journal:  J Allergy Clin Immunol       Date:  1978-05       Impact factor: 10.793

4.  Subsensitivity to the bronchodilator action of albuterol produced by chronic administration.

Authors:  H S Nelson; D Raine; H C Doner; W C Posey
Journal:  Am Rev Respir Dis       Date:  1977-11

5.  Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol in asthmatics.

Authors:  S Larsson; N Svedmyr
Journal:  Am Rev Respir Dis       Date:  1977-11

6.  Peripheral beta-adrenergic receptors concerned with tremor.

Authors:  C D Marsden; T H Foley; D A Owen; R G McAllister
Journal:  Clin Sci       Date:  1967-08       Impact factor: 6.124

7.  Dose-response effects of albuterol aerosol compared with isoproterenol and placebo aerosols: response to albuterol, isoproterenol, and placebo aerosols.

Authors:  S L Spector; M Garza Gomez
Journal:  J Allergy Clin Immunol       Date:  1977-04       Impact factor: 10.793

8.  Subsensitivity of beta responses during therapy with a long-acting beta-2 preparation.

Authors:  J W Jenne; T W Chick; R D Strickland; F J Wall
Journal:  J Allergy Clin Immunol       Date:  1977-05       Impact factor: 10.793

9.  The lymphocyte beta-adrenoceptor in normal subjects and patients with bronchial asthma: the effect of different forms of treatment on receptor function.

Authors:  M E Conolly; J K Greenacre
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

10.  A new method for measuring airway resistance in man using a body plethysmograph: values in normal subjects and in patients with respiratory disease.

Authors:  A B DUBOIS; S Y BOTELHO; J H COMROE
Journal:  J Clin Invest       Date:  1956-03       Impact factor: 14.808

View more
  19 in total

1.  Dose-response study with high-dose inhaled salmeterol in healthy subjects.

Authors:  J G Maconochie; J K Forster
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 2.  Risk/benefit ratio of long-term treatment with beta 2-adrenoceptor agonists.

Authors:  I Ziment
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 3.  Dose-response of inhaled drugs in asthma. An update.

Authors:  D J Clark; B J Lipworth
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

4.  Beta-adrenoceptor responses to inhaled salbutamol in normal subjects.

Authors:  B J Lipworth; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Systemic beta-adrenoceptor responses to salbutamol given by metered-dose inhaler alone and with pear shaped spacer attachment: comparison of electrocardiographic, hypokalaemic and haemodynamic effects.

Authors:  B J Lipworth; D G McDevitt; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

6.  Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects.

Authors:  J A Bennett; A E Tattersfield
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

Review 7.  Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.

Authors:  Mario Cazzola; Maria G Matera; Claudio F Donner
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  The role of inhaled and/or nasal corticosteroids on the bronchodilator response.

Authors:  Ju Kyung Lee; Dong In Suh; Young Yull Koh
Journal:  Korean J Pediatr       Date:  2010-11-30

9.  Regular nebulised terbutaline in chronic obstructive airways disease: dose-response studies fail to detect tolerance.

Authors:  C Teale; S B Pearson
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

10.  The effects of frusemide and triamterene on the hypokalaemic and electrocardiographic responses to inhaled terbutaline.

Authors:  D M Newnham; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.